Wir sind mit live! Mehr erfahren

Johnson & Johnson

JNJ

Börsenwert 616 Mrd. $

255,56 USD

+2,28

0,9 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

255,00

-0,56

0,22 %

1 Tag

0,9 %

5 Tage

-2,31 %

1 Monat

-4,38 %

3 Monate

2,24 %

6 Monate

8,96 %

Seit Jahresbeginn

23,25 %

1 Jahr

33,02 %

5 Jahre

59,61 %

10 Jahre

115,68 %

Profil: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Mitarbeiter: 140.800

Gesundheitswesen Arzneimittelhersteller – allgemein

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 53,2 %

Neutral 37,5 %

Negativ 9,4 %

The Motley Fool

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Bristol-Myers Squibb offers a deep focus on oncology and hematology with a favorable valuation. Johnson & Johnson provides a diversified mix of innovative medicine and a massive medical technology division.

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

Operational sales grew 6% in the third quarter of 2026. Full-year operational sales guidance increased to $100.7 billion at the midpoint.

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

24/7 Wall Street

The Stocks That Will Get Investors Home Safe When Tech Cracks

When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized.

The Stocks That Will Get Investors Home Safe When Tech Cracks

Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J pill in ulcerative colitis, and a discovery about ovaries after menopause.

Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin

24/7 Wall Street

Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience

A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it.

Procter & Gamble Has Raised Its Dividend for 70 Years. These 4 Stocks Also Reward Patience

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson (NYSE:JNJ) on Tuesday reported upbeat third-quarter results and raised its full-year guidance.

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Stock of the Day: Is this the Bottom for Johnson & Johnson?

Trading in Johnson & Johnson (NYSE:JNJ) is quiet Wednesday. The shares dropped by almost 6% yesterday after the company reported its earnings.

Stock of the Day: Is this the Bottom for Johnson & Johnson?

Zacks Investment Research

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt